Mirai Bio to Unveil Two Next Generation Programs for Targeted Nucleic Acid Delivery Beyond the Liver at ASGCT 2026
Mirai Bio, the innovation delivery partner for companies developing next generation nucleic acid medicines, today announced that it will present three abstracts at ASGCT 2026, including one oral presentation and two posters highlighting progress in two different targeted lipid nanoparticle delivery programs. Together, the presentations highlight both the rising bar for nucleic acid medicine delivery beyond the liver and how Mirai’s extensive proprietary, in vivo biodistribution data-powered machine learning approach enables best-in-class LNP design, improves selectivity and tolerability, and ensures functional performance in vivo across programs.
